Therma Bright's Venowave VW5 Secures Medicare Reimbursement Status Through HCPCS Code

Medical technology company Therma Bright Inc. has achieved a significant milestone with its Venowave VW5 compression therapy device receiving a permanent Healthcare Common Procedure Coding System code from the U.S. Centers for Medicare and Medicaid Services. This designation makes the Venowave VW5 the only Medicare-approved, reimbursable mobile mechanical compression system available in the United States, providing patients with an FDA-designated Durable Medical Equipment solution for managing post-operative recovery, pain, and swelling. The lightweight and compact medical compression pump offers a simple and comfortable treatment alternative for patients requiring compression therapy.

The company's market position has been strengthened through strategic distribution partnerships with major medical device distributors. DME Authority, a national distributor, has committed to a substantial inventory purchase including an initial order of 1,750 Venowave VW5 units, representing potential HCPCS code reimbursements of approximately $1.43 million. Another national distributor, Valor Medical, has placed an initial order for 100 units with expectations for regular future purchases. These distribution agreements demonstrate growing market acceptance and provide significant revenue potential for Therma Bright's compression therapy solutions.

The global compression therapy market presents substantial growth opportunities for Therma Bright's innovative products. According to Straits Research, the market was valued at $4.18 billion in 2024 and is projected to reach $6.72 billion by 2033, representing a compound annual growth rate of 7.30%. This market expansion is driven by increasing demand for non-invasive treatment options and growing awareness of compression therapy benefits for various medical conditions. The company's position in this rapidly expanding market segment provides significant potential for continued growth and market penetration.

Beyond the Venowave VW5, Therma Bright is developing additional innovative medical technologies that complement its compression therapy offerings. The company is pursuing FDA classification for its acoustic AI Digital Cough Technology, a remote therapeutic monitoring solution designed to help healthcare providers and epidemiologists collect and analyze respiratory data. This technology represents the company's expansion into digital health monitoring and aligns with growing trends in telehealth and remote patient monitoring. These strategic developments position Therma Bright as an emerging player in the medical device technology sector with potential for continued innovation across multiple healthcare segments.